ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1422

Evaluation of Salivary Gland Focus Score in Sjogren’s Disease Using Deep Learning: A Step Towards Tissue Biomarker Discovery

Konstantinos Panagiotopoulos1, Nikos Tsiknakis2, Dimitrios Zaridis3, Athanasios Tzioufas4, Dimitrios I. Fotiadis5 and Andreas Goules6, 1Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece, 2Karolinska Institutet, Department of Oncology-Pathology, Computational BioMedicine Laboratory, Foundation for Research and Technology Hellas, Stockholm, Sweden, 3School of Electrical & Computer Engineering and Biomedical Research Institute National Technical University of Athens and FORTH, Unit of Medical Technology and Intelligent Information Systems, Department of Materials Science and Engineering, University of Ioannina, Ioannina, Ioannina, Greece, 4LAIKO HOSPITAL, Athens, Greece, 5Unit of Medical Technology and Intelligent Information Systems, University of Ioannina & FORTH, Ioannina, Greece, 6GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece

Meeting: ACR Convergence 2024

Keywords: Bioinformatics, Biomarkers, Sjögren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 17, 2024

Title: Sjögren's Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Sjogren’s Disease (SjD) is characterized by focal sieladenitis in minor salivary gland biopsies (mSGB), which is evaluated using the Focus Score (FS). FS ≥ 1 identification is an integral part of the diagnostic approach and patient classification. However, during mSGB evaluation, FS is not reported in an astounding 17%[1], even among specialized academic centres. Moreover, even between experienced pathologists, some inter-observer variability is introduced[1]. As the need for reliable FS calculation and reporting is illustrated, the application of Artificial Intelligence in mSGB analysis shows promising potential and mandates to be explored.

Methods: A set of consecutive mSGBs was randomly selected from our archive, using only hematoxylin and eosin (H&E) staining. Three of them were excluded from analysis due to quality issues.  All biopsies were digitally scanned as Whole Slide Images (WSI). We split the dataset, with 70% as a training set and 30% as a test set. A Deep Learning model was developed for binary classification of mSGBs as positive (FS≥ 1) or negative (FS< 1).

Results: The final dataset comprised of 271 mSGBs of which 153 (56%) had FS< 1 and 118 (44%) had FS≥ 1.  In the FS≥ 1 subgroup, 74 (63%) were in the FS=1-2 range, while the remaining biopsies had FS >2 corresponding to the usual FS distribution among SjD population[2]. Our Supervised Learning classifier achieved an AUC=0.932, with a sensitivity of 87% and a specificity of 84%, displaying improvement in performance over previous work[3].

Conclusion: Developing an accurate Artificial Intelligence prediction model, we take a step towards reducing bias in focus score evaluation. Doing so in an automated manner potentially serves to expedite SjD diagnosis, while simultaneously allowing prognostic prediction, via Transfer Learning, which lays the foundations for novel tissue biomarker discovery.

[1]: Sebastian Costa et al. Reliability of histopathological salivary gland biopsy assessment in Sjögren’s syndrome: a multicentre cohort study, Rheumatology, Volume 54, Issue 6, June 2015, Pages 1056–1064, https://doi.org/10.1093/rheumatology/keu453

[2]: Chatzis L, Goules AV, …, Tzioufas AG. A biomarker for lymphoma development in Sjogren’s syndrome: Salivary gland focus score. J Autoimmun. 2021 Jul;121:102648. doi: 10.1016/j.jaut.2021.102648.
[3]: Basseto L et al. OP0232 DEEP LEARNING ACCURATELY PREDICTS FOCUS SCORE AND DIAGNOSIS OF PRIMARY SJÖGREN SYNDROME USING LABIAL SALIVARY GLAND BIOPSIES

Annals of the Rheumatic Diseases 2023;82:152-153.
[4]: Andreas V. Goules, Athanasios G. Tzioufas. “Primary Sjӧgren’s Syndrome: Clinical Phenotypes, Outcome and the Development of Biomarkers.” Autoimmunity Reviews, vol. 15, no. 7, July 2016, pp. 695–703, https://doi.org/10.1016/j.autrev.2016.03.004.

Supporting image 1


Disclosures: K. Panagiotopoulos: None; N. Tsiknakis: None; D. Zaridis: Pfizer, 2; A. Tzioufas: Pfizer, 2; D. Fotiadis: PD Neurotechnology, 11, Pfizer, 1; A. Goules: AbbVie/Abbott, 6, Amgen, 1, Pfizer, 2.

To cite this abstract in AMA style:

Panagiotopoulos K, Tsiknakis N, Zaridis D, Tzioufas A, Fotiadis D, Goules A. Evaluation of Salivary Gland Focus Score in Sjogren’s Disease Using Deep Learning: A Step Towards Tissue Biomarker Discovery [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-salivary-gland-focus-score-in-sjogrens-disease-using-deep-learning-a-step-towards-tissue-biomarker-discovery/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-salivary-gland-focus-score-in-sjogrens-disease-using-deep-learning-a-step-towards-tissue-biomarker-discovery/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology